Holen Sie sich die Stockscreener-App
4.73
6.97%
-0.36
Schlusskurs vom Vortag:
$5.09
Offen:
$5
24-Stunden-Volumen:
1.42M
Relative Volume:
0.42
Marktkapitalisierung:
$1.30B
Einnahmen:
$8.10M
Nettoeinkommen (Verlust:
$-92.72M
KGV:
-13.25
EPS:
-0.3571
Netto-Cashflow:
$-82.52M
1W Leistung:
+3.84%
1M Leistung:
-17.07%
6M Leistung:
+76.03%
1J Leistung:
+209.50%
1-Tages-Spanne:
$4.72
$5.04
1-Wochen-Bereich:
$4.4001
$5.125
52-Wochen-Spanne:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.745 | 1.39B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Taysha Gene Therapies commences underwritten public offering - MSN
Dip Buying: How liquid is Taysha Gene Therapies Inc stock2025 Support & Resistance & Entry Point Strategy Guides - baoquankhu1.vn
Trading Recap: Can PBYI generate free cash flowJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
VIX Spike: Is Taysha Gene Therapies Inc stock good for income investors2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
New Highs: Is Emerson Electric Co gaining market shareJuly 2025 Big Picture & High Conviction Investment Ideas - baoquankhu1.vn
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock - MarketBeat
Nagendran sells Taysha gene therapies (TSHA) stock for $942k By Investing.com - Investing.com Canada
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects - Insider Monkey
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
Buybacks Report: What is KIDSs TAM Total Addressable MarketIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.3%Should You Sell? - MarketBeat
Taysha Gene Therapies Advances TSHA-102 Program - MSN
Taysha Gene Therapies (TSHA) Stock Analysis: Unveiling a 114% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Is Taysha Gene Therapies Inc. stock a buy on dipsMarket Volume Report & High Conviction Investment Ideas - ulpravda.ru
Is Taysha Gene Therapies Inc. stock attractive for long term wealth buildingJuly 2025 Earnings & Detailed Earnings Play Alerts - ulpravda.ru
Is Taysha Gene Therapies Inc. stock vulnerable to regulatory risks2025 Technical Patterns & Fast Exit and Entry Strategy Plans - Улправда
Is Taysha Gene Therapies Inc. stock a bargain at current levelsJuly 2025 Summary & Verified Chart Pattern Signals - Улправда
Can Taysha Gene Therapies Inc. stock beat analyst upgradesMarket Performance Report & High Conviction Buy Zone Alerts - ulpravda.ru
Can Taysha Gene Therapies Inc. stock rebound after recent weaknessJuly 2025 PreEarnings & Smart Money Movement Alerts - Улправда
Should I hold or sell Taysha Gene Therapies Inc. stock in 2025July 2025 Action & Reliable Entry Point Alerts - Улправда
Will Taysha Gene Therapies Inc. stock benefit from green energy trendsJuly 2025 Recap & Low Risk High Win Rate Picks - ulpravda.ru
Taysha doses first patient in pivotal Rett syndrome gene therapy trial - Investing.com Nigeria
Chardan Capital Maintains Buy Rating on TSHA at $12 | TSHA Stock News - GuruFocus
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha doses first patient in pivotal Rett syndrome gene therapy trial By Investing.com - Investing.com South Africa
Taysha Gene Therapies (TSHA) Advances in Rett Syndrome Gene Ther - GuruFocus
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - The Manila Times
Taysha Gene Therapies, Inc.Common Stock (NQ: TSHA - FinancialContent
Wells Fargo Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Cuts Target Price to $11 - 富途牛牛
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Highlights: Can Taysha Gene Therapies Inc stock rebound after recent weaknessIPO Watch & Precise Buy Zone Tips - moha.gov.vn
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 4.8%What's Next? - MarketBeat
Breakthrough And Pullback | 3 Stocks Deserve Close Attention: AXSM, TSHA And KALV - Sahm
Taysha Gene Therapies, Inc. (TSHA)’s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+ - MSN
Rice Hall James & Associates LLC Buys New Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap UpHere's Why - MarketBeat
Taysha Gene Therapies stock hits 52-week high at $5.98 By Investing.com - Investing.com Nigeria
Taysha Gene Therapies stock hits 52-week high at $5.98 - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Does Taysha Gene Therapies Still Offer Value After a 196.8% Year to Date Surge? - Yahoo Finance
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? - Yahoo Finance
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades - Yahoo Finance
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program - Insider Monkey
Taysha Gene Therapies Earnings Notes - Trefis
Is Taysha Gene Therapies Inc. stock recession proofQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
How analysts rate Taysha Gene Therapies Inc. stock todayBull Run & Weekly Stock Breakout Alerts - Улправда
Earnings Report: Is Taysha Gene Therapies Inc. stock recession proofWeekly Stock Analysis & Risk Controlled Stock Alerts - Улправда
Breakouts Watch: Is Taysha Gene Therapies Inc. stock recession proof2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 1-Year HighTime to Buy? - MarketBeat
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):